AmyriAD buys Recognify to expand its cognition drug pipeline
What's the deal? AmyriAD TherapeuticsDealroom has a profile for this one. Try Dealroom → has acquired Recognify Life SciencesDealroom has a profile for this one. Try Dealroom → in an all-share transaction, adding Recognify's lead clinical-stage compound RL-007 (inidascamine) to its pipeline. The deal value was undisclosed. Recognify shareholders — including atai Life Sciences, Catalio Capital ManagementDealroom has a profile for this one. Try Dealroom → and the Sudhoff Family OfficeDealroom has a profile for this one. Try Dealroom → — become shareholders of AmyriAD.
What each side brings: AmyriAD is a clinical-stage biopharmaceutical company focused on cognition in central nervous system (CNS) disorders. Its lead asset, ismidenon (AD-101), targets cognitive decline in Alzheimer's disease. RL-007 is an orally administered compound that modulates cholinergic, glutamatergic and GABA-B receptor activity to address cognitive dysfunction.
What's the endgame? The deal deepens AmyriAD's cognition pipeline while preserving ismidenon as its lead Alzheimer's program. RL-007 adds a second development path in Cognitive Impairment Associated with Schizophrenia (CIAS), a large, underserved indication with no approved therapies targeting cognitive impairment.
Cognitive impairment is estimated to affect more than 80% of the roughly 24 million people living with schizophrenia worldwide.
Why now? RL-007 has been studied in 500 subjects and showed a consistent safety and tolerability profile, with no evidence of sedation, weight gain or extrapyramidal symptoms in its most recent Phase 2b study. A pharmacokinetic study started by Recognify is ongoing and will be completed by AmyriAD, with results expected in the first half of 2027.
What could go wrong? In the Phase 2b study (n=242), RL-007 did not meet statistical significance on the MCCB neurocognitive composite at week six. The company points to numerical improvements across several cognitive domains, including Symbol Coding, Speed of Processing and Verbal Learning, as grounds for a reformulated product and refined trial design.
"The Phase 2b data taught us a great deal about dose, exposure and endpoint selection," said Ranga Krishnan, chair of the board of AmyriAD. "We intend to apply those learnings to a reformulated product and a sharper clinical program in both CIAS and Alzheimer's disease."
Matthew P. Pando, president and chief executive officer of Recognify, said AmyriAD's "singular focus on cognition and its experienced CNS team make it the right owner to take inidascamine forward."
The signal: The acquisition reflects how clinical-stage biotechs are consolidating around narrow therapeutic focus — here, cognition — pooling assets and investors to pursue CNS indications where no approved treatments exist.
Read more: prnewswire.com
Image credit: Versal
